行情

CERC

CERC

Cerecor
NASDAQ

实时行情|Nasdaq Last Sale

5.03
-0.05
-0.98%
已收盘, 16:00 01/17 EST
开盘
5.14
昨收
5.08
最高
5.19
最低
5.01
成交量
6.31万
成交额
--
52周最高
7.65
52周最低
2.910
市值
3.26亿
市盈率(TTM)
-8.4467
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CERC 新闻

  • 波音接到美国空军警告:不满的还有我们
  • 新浪美股.4小时前
  • 收盘:财报季开局良好美股收高 道指本周累涨1.82%
  • 新浪美股.4小时前
  • 马斯克与谁共舞?
  • 中国经营报.5小时前
  • 美欧贸易谈判前景积极 欧洲股市创下历史新高
  • 新浪美股.5小时前

更多

所属板块

生物技术和医学研究
-0.10%
制药与医学研究
+0.07%

热门股票

名称
价格
涨跌幅

CERC 简况

Cerecor, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment. The Company owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions, including MDD, schizophrenia, Parkinson's disease and pathological gambling. Its COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, which is the dominant form of COMT.
展开

Webull提供Cerecor Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。